Retraction (The Oncologist, (2011), 16, 10, (1481), 10.1002/1873-3468.14351);MiR-449c targets c-Myc and inhibits NSCLC cell progression

FEBS Letters

Volumn 587, Issue 9, 2013, Pages 1359-1365

  Miao, Li Jun ^a   Huang, Shi Fu ^a   Sun, Zhen Tao ^a   Gao, Zeng Yan ^a   Zhang, Rui Xia ^a   Liu, Ying ^a   Wang, Jing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

c Myc; miR 449c; NSCLC; Proliferation

Indexed keywords

MICRORNA; MICRORNA 449C; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; GENE AMPLIFICATION; GENE FUNCTION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; ONCOGENE C MYC; PLASMID; PRIORITY JOURNAL; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

EID: 84876493330     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1002/1873-3468.14351     Document Type: Erratum

References (24)

1. X. Tan, W. Qin, L. Zhang, J. Hang, B. Li, and C. Zhang A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis Clin. Cancer Res. 17 21 2011 6802 6811 [Research Support, Non-US Gov't]
2. J.C. Soria, C. Massard, and T. Le Chevalier Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann. Oncol. 21 12 2010 2324 2332 [Evaluation Studies Research Support, Non-US Gov't Review]
3. R.H. Medema, C.C. Lin, and J.C. Yang Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC Clin. Cancer Res. 17 20 2011 6459 6466 [Review]
4. E.V. Prochownik C-Myc as a therapeutic target in cancer Expert Rev. Anticancer Ther. 4 2 2004 289 302 [ResearchSupport,US Gov't,Non-P.H.S. Research Support, US Gov't, P.H.S. Review]
5. J. Yoo, C.H. Kim, S.H. Song, B.Y. Shim, Y.J. Jeong, and M.I. Ahn Expression of caspase-3 and c-myc in non-small cell lung cancer Cancer Res. Treat. 36 5 2004 303 307
6. S. Ladu, D.F. Calvisi, E.A. Conner, M. Farina, V.M. Factor, and S.S. Thorgeirsson E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer Gastroenterology 135 4 2008 1322 1332 [Research Support, N.I.H., Intramural]
7. C.H. Chen, J. Shen, W.J. Lee, and S.N. Chow Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer Int. J. Gynecol. Cancer 15 5 2005 878 883 [Research Support, Non-US Gov't]
8. Z. Chen, H. Zeng, Y. Guo, P. Liu, H. Pan, and A. Deng MiRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc J. Exp. Clin. Cancer Res. 29 2010 151 [Research Support, Non-US Gov't]
9. M. Sachdeva, S. Zhu, F. Wu, H. Wu, V. Walia, and S. Kumar P53 represses c-Myc through induction of the tumor suppressor miR-145 Proc. Natl. Acad. Sci. USA 106 9 2009 3207 3212 [Research Support, N.I.H., Extramural. Research Support, US Gov't, Non-P.H.S.]
10. R.S. Pillai MicroRNA function: multiple mechanisms for a tiny RNA? RNA 11 12 2005 1753 1761 [Research Support, Non-US Gov't. Review]
11. I. Slezak-Prochazka, S. Durmus, B.J. Kroesen, and A. van den Berg MicroRNAs, macrocontrol: regulation of miRNA processing RNA 16 6 2010 1087 1095
12. S. Ji, G. Ye, J. Zhang, L. Wang, T. Wang, and Z. Wang MiR-574-5p negatively regulates Qki6/7 to impact beta-catenin/Wnt signalling and the development of colorectal cancer Gut 2012
13. J. Jiang, X. Zheng, X. Xu, Q. Zhou, H. Yan, and X. Zhang Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin PLoS One 6 8 2011 e23271 [Research Support, Non-US Gov't]
14. M. Folini, P. Gandellini, N. Longoni, V. Profumo, M. Callari, and M. Pennati MiR-21: an oncomir on strike in prostate cancer Mol. Cancer 9 2010 12 [Research Support, Non-US Gov't]
15. Z. Zhang, Z. Li, C. Gao, P. Chen, J. Chen, and W. Liu MiR-21 plays a pivotal role in gastric cancer pathogenesis and progression Lab. Invest. 88 12 2008 1358 1366 [Research Support, Non-US Gov't]
16. M. Feng, and Q. Yu MiR-449c regulates CDK-Rb-E2F1 through an auto-regulatory feedback circuit Cell Cycle 9 2 2010 213 214 [Editorial]
17. E. Gallardo, A. Navarro, N. Vinolas, R.M. Marrades, T. Diaz, and B. Gel MiR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer Carcinogenesis 30 11 2009 1903 1909 [Research Support, Non-US Gov't]
18. M. Incoronato, M. Garofalo, L. Urso, G. Romano, C. Quintavalle, and C. Zanca MiR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED Cancer Res. 70 9 2010 3638 3646 [Research Support, Non-US Gov't]
19. J.D. Roybal, Y. Zang, Y.H. Ahn, Y. Yang, D.L. Gibbons, and B.N. Baird MiR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1 Mol. Cancer Res. 9 1 2011 25 35 [Research Support, N.I.H., Extramural]
20. T. BouKheir, E. Futoma-Kazmierczak, A. Jacobsen, A. Krogh, L. Bardram, and C. Hother MiR-449c inhibits cell proliferation and is down-regulated in gastric cancer Mol. Cancer 10 2011 29 [Research Support, Non-US Gov't]
21. D. Iliopoulos, E.I. Bimpaki, M. Nesterova, and C.A. Stratakis MicroRNA signature of primary pigmented nodular adrenocortical disease: clinical correlations and regulation of Wnt signaling Cancer Res. 69 8 2009 3278 3282 [Research Support, N.I.H., Extramural. Research Support, Non-US Gov't]
22. L. Song, T. Dai, Y. Xie, C. Wang, C. Lin, and Z. Wu Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair J. Mol. Cell Biol. 4 2 2012 108 117 [Research Support, Non-US Gov't]
23. S. Sander, L. Bullinger, K. Klapproth, K. Fiedler, H.A. Kestler, and T.F. Barth MYC stimulates EZH2 expression by repression of its negative regulator miR-26a Blood 112 10 2008 4202 4212 [Research Support, Non-US Gov't]
24. Y.T. Chou, H.H. Lin, Y.C. Lien, Y.H. Wang, C.F. Hong, and Y.R. Kao EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF Cancer Res. 70 21 2010 8822 8831 [Research Support, Non-US Gov't]